oAlert.pl

Recalled Medicines & supplements – Current GIS Alerts 2026

Found 698 recalled products in the Medicines & supplements category. Check batch numbers, shops, and hazard information.

Common hazards in this category

All recalled products

Detimedac 500 mg – recalled product

Detimedac 500 mg

CRITICAL 03.07.2023

The pink discoloration may be caused by degradation of the active substance, which may pose an increased risk to the patient. Potential effects: lack of treatment efficacy, possible adverse reactions.

Detimedac 100 mg – recalled product

Detimedac 100 mg

CRITICAL 03.07.2023

Pink discoloration may be caused by degradation of the active substance, which may represent an increased risk to the patient. Potential effects: reduced treatment efficacy or unpredictable adverse reactions.

Lorabex – recalled product

Lorabex

CRITICAL 29.06.2023

It was suspected that the product might not meet quality requirements (out-of-specification results for lorazepam content and related substances), but testing of samples taken from the market confirmed correct quality of the batch. Potential effects: possible alteration of drug action, lack of efficacy or adverse effects.

Mebelin – recalled product

Mebelin

MEDIUM 26.06.2023

Due to the reduced values of active substance release in the product, the risk to patient health resulting from decreased drug efficacy cannot be excluded. Potential effects: lack of treatment efficacy, possible worsening of disease symptoms.

PALIFREN LONG – recalled product

PALIFREN LONG

MEDIUM 16.06.2023

A reduced content of the active substance paliperidone palmitate and an increased particle size compared to requirements were found, which may lead to reduced medicinal efficacy and a risk to patient health. Potential effects: reduced treatment efficacy, worsening of disease symptoms.

Duracef – recalled product

Duracef

MEDIUM 14.06.2023

Testing showed a lower value of cefadroxil release within 30 minutes, so a risk to patient health due to lack of drug efficacy cannot be excluded. Potential effects: lack of treatment effectiveness, possible disease complications.

APAP dla dzieci FORTE – recalled product

APAP dla dzieci FORTE

MEDIUM 26.05.2023

The suspension in the bottle contained gas bubbles, was foamed, had increased volume, and in several cases was non-uniform and separated into layers, which may indicate a significant quality defect of the medicine. Potential effects: incorrect dosing, reduced effectiveness, possible adverse reactions.

Tirosint Sol – recalled product

Tirosint Sol

HIGH 27.04.2023

Due to the probability of reduced active substance content in the product, the risk to patient health resulting from decreased effectiveness of the medicine cannot be excluded. Potential effects: lack of efficacy in treating thyroid disorders, worsening of health status, possible complications of concomitant diseases.

Tirosint Sol – recalled product

Tirosint Sol

HIGH 27.04.2023

A probability of reduced content of the active substance – levothyroxine sodium – was identified in some batches, which may lead to insufficient treatment efficacy. Potential effects: lack of thyroid disease control, complications, worsened well-being.

Tirosint Sol – recalled product

Tirosint Sol

HIGH 27.04.2023

Due to the probability of reduced active substance content in the product, the risk to patient health from decreased drug effectiveness cannot be excluded. Potential effects: lack of treatment efficacy, complications of the underlying disease.

Tirosint Sol – recalled product

Tirosint Sol

HIGH 27.04.2023

Due to the probability of reduced active substance content in the product, the risk to patient health resulting from decreased effectiveness of the medicine cannot be excluded. Potential effects: reduced treatment efficacy, possible worsening of thyroid disease symptoms.

Tirosint Sol – recalled product

Tirosint Sol

HIGH 27.04.2023

Due to the probability of reduced active substance content in the product, the risk to patient health resulting from decreased effectiveness of the medicine cannot be excluded. Potential effects: ineffective treatment, worsening of disease symptoms, complications resulting from thyroid hormone deficiency.

Tirosint Sol – recalled product

Tirosint Sol

MEDIUM 27.04.2023

A probability of reduced content of the active substance – levothyroxine sodium – was identified, which prevents guaranteeing proper medicinal quality and may lead to reduced therapeutic efficacy. Potential effects: reduced treatment effectiveness, risk of exacerbation of thyroid disease symptoms.

Tirosint Sol – recalled product

Tirosint Sol

MEDIUM 27.04.2023

Due to the probability of reduced active substance content in the product, the risk to patient health resulting from decreased effectiveness of the medicine cannot be excluded. Potential effects: reduced treatment efficacy, disease complications, deterioration of health status.

Tirosint Sol – recalled product

Tirosint Sol

MEDIUM 27.04.2023

Due to the probability of a reduced content of the active substance in the product, the risk to patient health resulting from decreased effectiveness of the medicine cannot be excluded. Potential effects: ineffective treatment of hypothyroidism, worsening of disease symptoms.

Tirosint Sol – recalled product

Tirosint Sol

MEDIUM 27.04.2023

Due to the probability of reduced active substance content in the product, the risk to patient health resulting from decreased effectiveness of the medicine cannot be excluded. Potential effects: reduced treatment effectiveness, worsening of disease symptoms.

Tirosint Sol – recalled product

Tirosint Sol

MEDIUM 27.04.2023

Due to the probability of reduced active substance content in the product, the risk to patient health resulting from decreased effectiveness of the medicine cannot be excluded. Potential effects: lack of treatment efficacy, disease worsening.

Tirosint Sol – recalled product

Tirosint Sol

MEDIUM 27.04.2023

Due to the probability of reduced active substance content in the product, a risk to patient health resulting from decreased efficacy of the medicine cannot be excluded. Potential effects: reduced treatment efficacy, possible worsening of thyroid disease control.

Sirdalud MR – recalled product

Sirdalud MR

HIGH 07.04.2023

It was found that batch KDF58 does not meet the requirements for the mean value of tizanidine hydrochloride release at 2 hours, and the cause of this deviation is unknown, so the impact on product quality, safety of use and the risk to patients’ health cannot be predicted. Potential effects: overdose or insufficient drug effect, treatment complications.

Vectibix – recalled product

Vectibix

CRITICAL 05.04.2023

The quality defect could cause leakage and loss of sterility of the medicine, creating a risk of microbial contamination and serious adverse reactions, posing a threat to the patient’s health and life. Potential effects: infection, severe complications, sepsis, life-threatening conditions.

What to do if you bought a recalled product?

If you have purchased any of the products listed above, stop using or consuming them immediately. You can return the product to the store where you bought it for a full refund. Keep the receipt if possible, but most stores will accept returns even without one.